Nowhere are community, connections, and intersections more important than they are in terms of improving diversity, equity, and inclusion in clinical trials.
Though some challenges will be naturally mitigated as the decentralized clinical trial (DCT) process matures, others have demonstrated why DCTs will never be a one-size-fits-all solution for patients and clinical trial teams.
Even as the industry recognizes the benefits of DCTs, it is wading through the complexities of how to implement the model most effectively and at scale through an ecosystem of best-of-breed, trial-enablement providers.
On top of the current regulatory limbo, digital therapeutics manufacturers face many of the same clinical trial challenges as traditional drug makers, including those tied to patient recruitment and retention, quality of data, and costs.
Moving beyond function-specific solutions can enable a more connected, digital clinical trial. Here are four ways this can streamline processes to boost efficiencies for sites.
